Transfection reagents
View Patent ↗Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH 2 )l, or {(CH 2 )i-Y—(CH 2 )j}k, wherein Y is selected from the group consisting of CH 2 , an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X 1 -L′-X 2 -Z or -Z; R 1 –R 6 , independently of one another, are selected from the group consisting of H, —(CH 2 )p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and wherein at least one of R 1 , R 3 , R 4 and R 6 is a straight chain or branched, cyclic, alkyl, alkenyl, alkynyl or aryl group; and anyone of R 1 , R 3 , R 4 and/or R 6 may optionally be covalently linked with each other, with Y or with L when L is C or CH to form a cyclic moiety; Z is selected from the group consisting of amine, spermiyl, carboxyspermiyl, guanidyl, spermidinyl, putricinyl, diaminoalkyl, pyridyl, piperidinyl, pyrrolidinyl, polyamine, amino acid, peptide, and protein; X 1 and X 2 , independently of one another, are selected from the group consisting of NH, O, S, alkylene, and arylene; L′ is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, alkylene ether, and polyether; D is Q or a bond; A 1 and A 2 , independently of one another, are selected from the group consisting of CH 2 O, CH 2 S, CH 2 NH, C(O), C{NH), C(S) and (CH 2 )t; X is a physiologically acceptable anion; m, n, r, s, u, v, w and y are 0 or 1, with the proviso that when both m and n are 0 at least one of r, s, u and y is other than 0; i, j, k, l, p and are integers from 0 to about 100; q is an integer from 1 to about 1000; and a is the number of positive charge divided by the valence of the anion.
1. A compound having the formula:
2. A composition comprising the compound of claim 1 solubilized in aqueous medium.
3. The composition of claim 2 further comprising a neutral lipid.
4. The composition of claim 2 further comprising DOPE, DOPC or cholesterol.
5. A kit comprising a container means which comprises a compound having the formula:
6. The kit of claim 5 wherein the compound is solubilized in aqueous medium.
7. The kit of claim 6 wherein the aqueous medium further comprises a neutral lipid.
8. The kit of claim 6 wherein the aqueous medium further comprises DOPE, DOPC or cholesterol.
9. A method for introducing a nucleic acid into a cell, the method comprising the steps of:
contacting a compound having the formula:
with the nucleic acid for at least 15 minutes to form a complex; and incubating the complex with the cell.
10. The method of claim 9 wherein the contacting step and the incubating step are conducted in physiological medium.
11. A method for introducing a nucleic acid into a cell, the method comprising the steps of contacting a composition comprising a compound having the formula
solubilized in aqueous medium with the nucleic acid for at least 15 minutes to form a complex; and incubating the complex with a cell.
12. The method of claim 11 wherein the contacting step and the incubating step are conducted in physiological medium.
13. The method of claim 11 wherein the composition comprises a neutral lipid when it contacts the nucleic acid.
14. The method of claim 11 wherein the composition comprises DOPE, DOPC, or cholesterol when it contacts the nucleic acid.
15. A lipid aggregate made by mixing a compound having the formula
with a neutral lipid.
16. The lipid aggregate of claim 15 , wherein the neutral lipid is DOPE, DOPC or cholesterol.
17. The lipid aggregate of claim 15 , wherein the lipid aggregate is 50 to 200 nm in diameter.
18. The lipid aggregate of claim 15 , wherein the lipid aggregate is formed using extrusion, freeze-thaw, or sonication.
19. A method for making a lipid aggregate, comprising mixing a compound having the formula
with a neutral lipid to form the lipid aggregate.
20. The method of claim 19 , wherein the lipid aggregate is made by mixing the compound with the neutral lipid DOPE, DOPC or cholesterol.
21. The method of claim 19 , wherein the mixing is performed to obtain a lipid aggregate having a diameter of 50 to 200 nm.
22. The method of claim 19 , wherein the lipid aggregate is formed using sonication, freeze-thaw, or extrusion.